her2/neu will emerge as the most potent targeted therapy.
, which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185 her2/neu and ErbB3. In our studies of epidermal growth factor receptor (EGFR)-p185
her2/neu heterodimerization, we noted that 2C4 formed associations with the EGFR-p185 her2/neu receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185 her2/neu , but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185 her2/neu will emerge as the most potent targeted therapy. Oncogene (2008) 27, 3870-3874; doi:10.1038 /onc.2008 published online 11 February 2008 Keywords: her2; Pertuzumab; heterodimer; 4D5 p185 her2/neu (Neu, c-ErbB2), a protein product related to the oncogene neu and the second member of the ErbB family of receptor tyrosine kinases, is overexpressed in many breast and ovarian cancers (van de Vijver et al., 1987; Slamon et al., 1989) , early breast tumors (Lodato et al., 1990) , gastrointestinal tumors , lung tumors (Kern et al., 1990) as well as tumors of the pancreas (Williams et al., 1991) . Extensive studies have shown that p185 her2/neu , acting as the preferred co-receptor for other family members, plays a dominant role in mediating the malignant phenotype Kokai et al., 1989; Lodato et al., 1990) . p185
her2/neu -targeted therapy was initiated more than 20 years ago when monoclonal antibodies were used to reverse the malignant phenotype (Drebin et al., 1984 (Drebin et al., , 1985 . Since then, significant efforts have been spent to improve antibodies disabling p185 her2/neu . The humanized antibody 'trastuzumab' (rhumAb 4D5 or Herceptin) (Carter et al., 1992) is already used to treat advanced breast cancer and, more recently, as an adjuvant to prevent tumor emergence (Katsumata et al., 1995; Romond et al., 2005) .
2C4 (Pertuzumab, Omnitarg) is a distinct recombinant humanized monoclonal antibody targeting a different epitope on the extracellular domain of the p185 her2/neu receptor. Agus et al. (2002) suggested that 2C4 disrupts the association of p185
her2/neu with all other ErbB family receptors. This hypothesis was based on the 2C4 influence on p185 her2/neu -ErbB3 association. We first identified homodimers of p185 her2/neu and heterodimers of epidermal growth factor receptor (EGFR) with p185 her2/neu some years ago (Wada et al., 1990b) . Moreover, we have defined interface binding molecules that do interfere with all heteromeric associations of the ErbB family (Berezov et al., 2002) . In this study, we sought to investigate the effect of 2C4 preincubation on heteromeric EGFRp185 her2/neu interactions. Here, 'preincubation' refers to contacting cells on tissue culture plate with the antibody. Cells were washed twice with phosphate-buffered saline (PBS) before they were lysed to release membrane and cytoplasmic proteins.
Experiments were performed with SKBR3, a breast cancer cell line expressing EGFR, p185 her2/neu and ErbB3. EGF stimulation led to strong phosphorylation of EGFR, as revealed by the pEGFR(Y1173) antibody (Figure 1a) . Preincubation of 2C4 did not significantly prevent phosphorylation of EGFR on residue Tyr 1173 . 2C4, however, formed discernible complexes with p185 her2/neu -EGFR heteromers during the preincubation, as p185 her2/neu and EGFR were detected in the protein G-agarose pulled down from the lysates of cells preincubated with 2C4 ( Figure 1b) . As 2C4 is specific to p185 her2/neu , EGFR was co-precipitated with p185 her2/neu . EGFR in the complex with p185 her2/neu appeared to be already phosphorylated on Tyr 1173 , even before EGF stimulation.
The observation that the p185 her2/neu and associated proteins formed a stable complex with the preincubated antibodies and subsequently were pulled down by protein G-agarose is not limited to 2C4. 4D5, when preincubated with intact SKBR3 cells, also formed stable complexes with receptors. Consequently, both EGFR and ErbB3 were co-precipitated after protein G pull-down (Figure 2) . Interestingly, the receptor complexes captured by 2C4 and 4D5 showed distinct contents of heteroreceptors. Using SKBR3 cells preincubated with 2C4 or 4D5 and subsequently stimulated with heregulin (HRG)-b1, we demonstrated that the 2C4 complex contained more EGFR but much less ErbB3 than the 4D5 complex (Figure 2 ). The less favored binding of 4D5 to the EGFR-p185 -ErbB3 heterodimer as we discussed later. These data indicate that significant her2/neu complexes exist in these cells, even in the presence of 2C4.
We have tested several cell lines with different levels of EGFR and p185 her2/neu . Both SKBR3 and BT474 express very high level of p185 her2/neu , but EGFR levels in BT474 are very low. A431 has high levels of EGFR and medium levels of p185 her2/neu . Co-precipitated EGFR was detected in A431 cells in addition to SKBR3 cells, although the signal from A431 cells was weaker than that from SKBR3 cells (Supplementary Figure S1) . In BT474 cells, although large amounts of p185 her2/neu captured by 2C4 were pulled down by protein G beads, EGFR was rarely detected, possibly due to much lower expression levels of EGFR in this cell line (Supplementary Figure S1 ). MCF7, a cell line expressing low levels of EGFR and p185 her2/neu , did not reveal any EGFR co-precipitation by 2C4 under similar conditions (data not shown).
In summary, our data indicated that 2C4 functions by a mechanism other than a general ErbB dimerization blocker. First, 2C4 stabilizes, instead of blocking, p185 her2/neu -EGFR dimerization. Second, 2C4 also has a weak affinity for p185 her2/neu -ErbB3 complexes, and the presence of 2C4 might reduce but not abolish p185 her2/neu -ErbB3 association. The effect of 2C4 on the p185 her2/neu -ErbB3 heterodimers is significantly different from that reported by Agus et al. (2002) , in which 2C4 dramatically and almost completely inhibited p185 her2/neu -ErbB3 associations. In that report, p185
her2/neu -ErbB3 interaction was studied her2/neu and epidermal growth factor receptor (EGFR). SKBR3 was routinely cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 2 mM glutamine, 1 Â penicillin/streptomycin. SKBR3 cells were serum-starved overnight and preincubated with anti-p185 her2/neu antibody 2C4 (20 mg ml
À1
, lanes 2 and 4). Cells were challenged with EGF (100 ng ml
, lanes 3 and 4) for 10 min at 37 1C and washed twice with phosphate-buffered saline containing 5 mM NaF and 4 mM Na3VO4. Cell lysates were prepared in RPMI lysis buffer (Agus et al., 2002) . ) for a 10-min stimulation at 37 1C. Cells were washed twice with phosphate-buffered saline (PBS) containing 5 mM NaF and 4 mM Na3VO4 and lysed in RPMI lysis buffer (Agus et al., 2002) . Cell lysates were cleared by centrifugation and subjected to protein G pull-down or 4D5 immunoprecipitation (IP). For protein G pull-down (lanes 1-3), cell lysates were contacted directly with protein G agarose beads. Antibodies (2C4 and 4D5) that were preincubated with cells sustained the PBS washing and remained bound to the receptors. Thus, receptor complexes captured by the preincubating antibodies were pulled down by protein G beads. For 4D5 IP, cell lysates from cells preincubated with or without antibodies were contacted first with additional 4D5 (5 mg) for 1 h at 4 1C and then with protein G agarose beads. Beads were collected by centrifugation and washed three times by lysis buffer. SDS sample buffer was added to the beads, and samples were boiled for 5 min before SDS-polyacrylamide gel electrophoresis. Separated proteins were transferred to nitrocellulose membrane for western blot. Membranes were blocked in 5% nonfat milk in PBS overnight. The following antibodies were used for blot: EGFR, clone 1005; ErbB3, C-17 (HRP) (Santa Cruz Biotech). EGFR, epidermal growth factor receptor. Other laboratories also studied the effect of 2C4 on the dimerization of ErbB receptors, but the data are neither uniform nor convincing. Mendoza et al. (2002) reported that 2C4 inhibited p185 her2/neu and ErbB3 association, which was induced by low-dose HRG (1 nM). Takai et al. (2005) studied the dimerization of EGFR and p185 her2/neu . Although immunoprecipitation experiments were used to demonstrate EGFR and p185 her2/neu dimerization in OVCA433 cells, 2C4 inhibition of dimerization was only shown in a contrived eTag assay. 2C4 was not studied by conventional biochemical immunoprecipitations. It should be noted that coprecipitation experiments disclose proteins associated in a complex, whereas the eTag assay reveals proteins in an extended proximity of 200 nm. Jackson et al. (2004) also studied EGF-and HRG-induced receptor activation. However, 2C4 was only examined for its effect on receptor phosphorylation, but not on heteromeric associations.
2C4 binding to heteroreceptors
Our data on heteroreceptor preferences by 2C4 and 4D5, for the first time to our knowledge, also indicate that p185 her2/neu may use different sets of surface residues for heterodimerizing with different ErbB family receptors. The 2C4 epitope in p185
her2/neu appears to be involved in the heterodimerization with ErbB3, but less so with EGFR. In contrast, the 4D5 epitope plays a greater role in the heterodimerization with EGFR.
To understand the role of the 2C4 epitope, we developed a structural model of the EGFR-p185 her2/neu heterodimer based on ErbB structures available from the RCSB protein data bank (PDB). The EGFR homodimer structure (PDB ID: 1IVO) (Ogiso et al., 2002) was selected as the most appropriate structural template, although information on subdomain IV was missing. By superimposing domain III and IV from the tethered form of EGFR (PDB ID: 1NQL) (Ferguson et al., 2003) onto domain III of the dimeric form, we obtained a homodimeric structure of the full-length EGFR ectodomain. Finally, we replaced one of the two EGFR molecules in the model with p185 her2/neu (PDB ID: 1N8Z) by superimposing residues 232-292 of p185 her2/neu onto EGFR residues 226-286. The domain II region of the dimer is shown in Figure 3a .
The only available ErbB3 structure is in the tethered (inactive) form (PDB ID: 1M6B) (Cho and Leahy, 2002) . Modeling is very unlikely to produce an accurate extended form for the whole extracellular domains. However, EGFR and ErbB3 share significant similarities in each subdomain. Therefore, we have superimposed domain II of ErbB3 onto the domain II of EGFR in the EGFR-p185
her2/neu heterodimer model to generate the ErbB3-domainII/p185
her2/neu heterodimer model (Figure 3b) .
The crystal structure of 2C4-p185 her2/neu complex (Franklin et al., 2004) Figure 3a ). The models are consistent with our data, revealing that the 2C4 epitope in p185 her2/neu , although important for the heterodimerization with ErbB3, is not as critical for the heterodimerization with EGFR. In addition, using a docking program Autodock 4.0.1 (Sanner, 1999) , we were able to demonstrate that 2C4 can be docked back to p185 her2/neu as well as the EGFR-p185 her2/neu heterodimers, but not to the p185 her2/neu -ErbB3 heterodimer (Supplementary Figure S2) . According to the docking program, 2C4 binds to p185 her2/neu monoreceptor with lower energy than it does with the EGFRp185 her2/neu heterodimers (À11.93 vs À6.8 kcal mol À1 ). The dimers of ErbB receptors adopt the shape of an elliptic disk with a hollow center. The two halves of the disk contact each other mainly through domain II and IV. Whereas 2C4 binds to domain II of p185 her2/neu , 4D5 binds to a different epitope in domain IV. In addition, 2C4 and 4D5 orient differently with respect to the dimer disk after binding to p185 her2/neu . 2C4 binds to domain II perpendicularly, whereas 4D5 binds to domain IV in a parallel position to the disk (Figure 3c) .
The 4D5 epitope appears to be involved in ErbB receptor dimerization. Using constrained peptides mimicking cystine knot in domain IV, Berezov et al. (2002) , has higher affinity to EGFR than ErbB3. Another peptide B2-S23-BPT, which contains a sequence C terminal to B2-S22-APE (amino acid 605-632), prefers ErbB3 to EGFR. Interestingly, the 4D5 epitope covers B2-S22-APE but not B2-S23-BPT . By binding to a sequence critical to EGFR-p185 her2/neu complexes, 4D5 in the parallel orientation can pose as a steric hindrance for the proper alignment of EGFR. This explains why in the presence of 4D5 there were less EGFR-p185 her2/neu complexes. The subtle effect of 4D5, if any, on the p185 her2/neu -ErbB3 complexes is also due to the steric disturbance to the dimerization region. In contrast, because of the way 2C4 latches onto p185 her2/neu , 2C4 will mediate strong 2C4 binding to heteroreceptors Z Cai et al inhibition only when its epitope is critically involved in dimerization.
Our studies have indicated that 2C4 and 4D5 complement each other in their ability to capture different sets of heteroreceptors. We are optimistic about using 2C4 together with other antibodies targeting different epitopes (for example, 4D5) or different ErbB receptors (for example, C225) in an antibodycocktail therapy, a strategy we proposed first many years ago for this family of receptors (Drebin et al., 1988; Wada et al., 1990a) . Interactions among ErbB receptors have been implicated in the acquired resistance to tyrosine kinase inhibitors to EGFR (Kwak et al., 2005; Sergina et al., 2007) . An antibody cocktail might efficiently disable p185 her2/neu homomeric and heteromeric associations and limit the emergence of resistance caused by ErbB3 hetero-associations. . p185 her2/neu was colored in blue, with the six residues for 2C4 binding colored in magenta. 4D5-binding sites derived from the 4D5-p185 her2/neu complex structure were colored in red. Ribbon diagram of 2C4 and 4D5 were colored in green and gray, respectively. We followed the approach described by Franklin et al. (2004) for the modeling of the p185 her2/neu heterodimer. The superposition was performed with Swiss-Pdb Viewer (Guex and Peitsch, 1997) . Energy minimization was carried out using Discover within InsightII 98.0, a molecular modeling package (Molecular Simulation Inc., San Diego, CA, USA).
